Private Equity

The Raine Group hires Credit Suisse veteran Anthony Kontoleon, signaling a major push to dominate TMT advisory ahead of an anticipated tech boom.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

The major CRO acquisition deepens Worldwide's oncology and FSP capabilities, signaling a strategic move in the consolidating clinical research market.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

Bain Capital and Goldman Sachs finance Truelink's acquisition of SouthernCarlson, signaling private credit's growing power in middle-market deals.

As Churchill Capital XI's shares and warrants begin separate trading, what does this mean for investors and the hunt for Michael Klein's next big deal?

Following its majority stake acquisition from ExxonMobil, Canadian firm North Atlantic details its offer to fully control a key French refiner.

RedBird Capital Partners cements its control over AC Milan with a major refinancing deal, clearing debt to Elliott and paving the way for a new stadium.

Asante Gold boosts its war chest with a C$13.8M private placement led by its own chairman, fueling aggressive expansion at its Ghanaian gold mines.

Ferguson Wellman projects a fourth year of market growth, defying skeptic fears, while navigating major wealth planning changes from the ‘Tax Act of 2025’.

In a planned leadership evolution, Daryl Seaton becomes CEO as founder Bill Sowell targets M&A, positioning the RIA for its next chapter of expansion.

Sichenzia Ross Ference Carmel LLP leveraged its deep expertise in complex securities to advise on over $14 billion in deals, outperforming in a hot market.

Wendel Investment Managers' affiliates raise over €11 billion, validating the firm's strategic pivot and defying a tough private capital market.

As Moelis & Co. prepares to report its 2025 results, investors are watching to see if the firm capitalized on a record year for dealmaking.

MIT economist Andrew Lo joins the Global Coalition for Adaptive Research, bringing Wall Street strategies to revolutionize clinical trials for rare diseases.

Amid a national shortage of over 7M homes, National Equity Fund's record 2025 investments and innovative financing created 14,200 affordable units.

Guggenheim Investments' new $250M vehicle, backed by LGT Capital Partners, highlights the strategic depth and enduring allure of the private credit market.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

A new alliance pairs Relation's 'Lab-in-the-Loop' AI with Deerfield's investment might, aiming to fast-track novel drugs for intractable diseases.